Collectively, we establish H3K18la as a crucial epigenetic driver of TROP2‐mediated CRLM progression and propose that disrupting the H3K18la–TROP2 feedback loop offers a novel therapeutic strategy against CRC metastasis. The gene discussed is TACSTD2; the disease is colorectal carcinoma.